A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer

BACKGROUND: Pemetrexed and cisplatin is a first-line standard in non-squamous non-small-cell lung cancer without targetable mutations. It became the backbone of checkpoint-inhibitor–chemotherapy combinations. Single high doses of cisplatin pose toxicity risks and require hyperhydration, potentially...

Descripción completa

Detalles Bibliográficos
Autores principales: Metzenmacher, Martin, Kopp, Hans-Georg, Griesinger, Frank, Reinmuth, Niels, Sebastian, Martin, Serke, Monika, Waller, Cornelius Florian, Thomas, Michael, Eggert, Jochen, Schmid-Bindert, Gerald, Hoiczyk, Mathias, Christoph, Daniel Christian, Kimmich, Martin, Deuß, Burkhard, Seifert, Stephanie, Held, Swantje, Schuler, Martin, Herold, Thomas, Breitenbuecher, Frank, Eberhardt, Wilfried Ernst Erich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164550/
https://www.ncbi.nlm.nih.gov/pubmed/34104223
http://dx.doi.org/10.1177/1758835921996506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164550/
https://www.ncbi.nlm.nih.gov/pubmed/34104223
http://dx.doi.org/10.1177/1758835921996506

Ejemplares similares